A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Clinical trial NCT05919069 · COMPLETED

Trial details

NCT number: NCT05919069
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatic Impairment

Start date: 2023-06-16
Primary completion: 2024-09-16
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.